

FORM 7**MONTHLY PROGRESS REPORT**Name of Listed Issuer: Stillcanna Inc. (the "Issuer").Trading Symbol: STILNumber of Outstanding Listed Securities: 110,874,727Date: July 8, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

1. Provide a general overview and discussion of the activities of management.

Further to the announcement made on 21 April 2020, effective June 2, 2020, the Company signed a definitive agreement to acquire Sativa Group PLC. Completion of the Proposed Transaction will be subject to the Company obtaining the approval of the CSE, as well as the approval of a majority of Stillcanna shareholders at the

Stillcanna shareholder meeting to be held as soon as possible pursuant to the policies of the CSE.

The Company announced that it has begun its Novel Food Application and has hired Global Regulatory Services of the UK, an award winning global consulting firm with a specialty in Novel Food applications. The Company has submitted its active ingredients for both stability and toxicology. As required within certain EU markets the Company intends to have its Novel Food Application validated prior to the February 2021 deadline and remain market compliant in 2021 and beyond.

The Company continues to work on updating its permits at its Polish facility. This certification will allow the use of the Company's CBD as an ingredient in various behind the counter products.

2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Company announced that it has begun its agricultural initiatives in Europe to secure a steady availability of hemp biomass for the Company's NEXUS extraction facility in Poland for 2020 and 2021.

This year the Company has taken a multi-pronged approach to its farming initiatives including planting on certified organic land. The Company's certified organic initiative could yield up to 100,000 kilos of premium organic hemp. Having a certified organic product allows the Company to access a wider range of specialty customers.

The Company's strategy of using its own farming complimented with agricultural partnerships is designed to assure the Company access to highest CBD content biomass available in Europe, while reducing agricultural risks.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Company announced that it has signed a supply agreement with Brains Bioceutical Corp to supply bulk CBD for processing to their European operations. Brains is a global leader of plant-based cannabidiol (CBD) as an Active Pharmaceutical Ingredient (API) for both Pharmaceutical and Nutraceutical use. Brains is one of the few certified phyto-cannabinoid CBD API manufacturers

in Europe. Brains' CBD API has GMP certification (MHRA) for both human and veterinary use. Brains API is currently being used in various clinical trials around the globe.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to Report.

7. Describe the acquisition of new customers or loss of customers.

The Company along with its own agricultural efforts in Poland has agreements with multiple European based hemp farmers to assure the Company high CBD content EU compliant hemp biomass for 2020. All of the Company's own biomass will be farmed organically and follow Good Farming Practices. The Company anticipates processing a minimum of 18,000 kilos of biomass in its Polish facility every month but could double that amount should the market demand be there.

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to report

9. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None to report

10. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

11.

None to report

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report

13. Provide details of any securities issued and options or warrants granted.

None to report

14. Provide details of any loans to or by Related Persons.

None to report

15. Provide details of any changes in directors, officers or committee members.

None to Report

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Company, although still in a strong treasury position has implemented cost-saving measures during this unsettled global environment due to the COVID 19 pandemic.

In January 2019, the European Commission updated the Novel Food Catalogue to state that extracts of Cannabis sativa L. and derived products containing cannabinoids are considered as novel foods, as a history of consumption has not been demonstrated. As a result, all extracts of hemp and derived products containing cannabinoids (including CBD) are now regarded by the European Commission as novel.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were/is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated July 8, 2020.

Joel Leonard

Name of Director or Senior Officer

DocuSigned by:

Joel Leonard

Signature

CFO

Official Capacity

Issuer Details		For Month	Date of Report
Name of Issuer		End	08/07/20
Stillcanna Inc.		June 2020	
Issuer Address			
503-905 Pender St. W			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Vancouver/BC/V6C1L6		()	()
Contact Name		Contact Position	Contact Telephone No.
Joel Leonard		CFO	604-239-0840
Contact Email Address		Web Site Address	
joel@stillcanna.com		www.stillcanna.com	